Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vladimir Coric
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 274
- Beta
- 3.17
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.10
Financials
Revenue
$0.00-100.0%Net Income
$-137.31MEBITDA
$-132.29MFree Cash Flow
$-85.55MEPS (diluted)
$-0.91Shares Outstanding (diluted)
150.64M+1050.9%Operating Expenses
$124.90MCash & Debt
$267.87MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-738.82M | $-6.86 |
| 2024 | $0.00 | $-846.42M | $-9.28 |
| 2023 | $0.00 | $-408.17M | $-5.73 |
| 2022 | $0.00 | $-570.28M | $-12.75 |
| 2021 | $0.00 | $-213.80M | $-5.97 |
| 2020 | $0.00 | $-118.67M | $-3.31 |
| 2019 | $0.00 | $-528.80M | $-10.91 |
Valuation
BHVNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (10)
- Newsbenzinga.com·1d ago·Negative
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
View source ↗ - Newsprnewswire.com·28d ago·Neutral
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient …
View source ↗ - Newsbarrons.com·29d ago·Negative
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
View source ↗ - Newsreuters.com·29d ago·Negative
US FDA pauses new enrollment in Biohaven's epilepsy drug trials Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down more than 13% in premarket trading.
View source ↗ - Newsfool.com·42d ago·Negative
Why Biohaven Stock Was Rocking the Market This Week Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.
View source ↗ - Newsseekingalpha.com·43d ago·Neutral
…es a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs, and extends the funding runway, addressing prior liquidity concerns. I am upgrading BHVN to Buy, citing promising degrader pipeline assets targeting large autoimmune markets and pivotal trial initiations.
View source ↗ - Newszacks.com·43d ago·Neutral
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
View source ↗ - Newsbenzinga.com·44d ago·Neutral
Why Is Biohaven Stock Soaring Wednesday? Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing agreement with SK Biopharmaceuticals Co. Ltd. and secured a legal victory alongside Yale University in a trade-secret dispute.
View source ↗ - Newsreuters.com·44d ago·Negative
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million Biohaven has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals for Biohaven's epilepsy drug platform, including Opakalim, for up to $795 million, the companies said in a statement on Wednesday.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd.
View source ↗
Earnings
Mon, Nov 9(in 4 weeks)
Consensus estimate $-0.61 per share
Typical surprise -2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.91 vs $-0.76miss
- Mon, May 4$-0.88 vs $-0.86miss
- Mon, Mar 2$-1.21 vs $-1.22beat
- Mon, Nov 10$-1.64 vs $-1.91beat
- Mon, Aug 11$-1.94 vs $-1.94beat
- Mon, May 12$-2.17 vs $-1.67miss
Estimates and results for BHVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BHVN officers and directors.
- Bought
- $52.8m
- Sold
- —
23 trades
0 trades
- Clark George C.bought
- Bailey Gregorybought
- Childs John Wbought
- Coric Vladbought
- Coric Vladbought
- Childs John Wbought
- Childs John Wbought
- Childs John Wbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BHVN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.